+ News&Events
 
Home News&Events News
News
Provide:Anidulafungin,Echinocandin B,Caspofungin,Micafungin,Amphotericin B
2011-9-3

New antifungal
Avidin Echinococcus by inhibiting the fungal cell wall β-glucan biosynthesis and a bactericidal effect. Some new drugs undergoing clinical trials. Early data indicate that a variety of Echinococcus avidin with anti-Candida, some endemic fungi (Histoplasma, such as capsule), Aspergillus and Pneumocystis carinii activity, but no activity against Cryptococcus neoformans.
Lung concept developed by Merck is given a new antifungal agents (MK-0991, L-743 872), to treat fluconazole-resistant Candida species, some endemic fungal disease, the card Pneumocystis carinii disease may also be effective. Avidin Echinococcus now being given to read and lung stage Ⅰ and Ⅱ clinical trial.
Nick ADM Z is a bactericidal anti-fungal, inhibit fungal cell wall chitin synthase (chitin synthase), in vitro tests and animal trials prove Coccidioides immitis, dermatitis blastomycosis and histoplasmosis capsule has an excellent antibacterial activity, and other anti-Candida drug synergy. Has reached its pharmacokinetic parameters, there are two kinds of oral and intravenous formulations, early completion of Coccidioides immitis disease clinical research.
Padi ADM is a unique role of antifungal agents, its mechanism is calcium-dependent binding to fungal cell wall, with Candida and Aspergillus killing effect, the drug is still in its earliest days, not sure of its efficacy and toxicity .
Combination of antifungal agents better than single drugs, the theoretical basis of two drugs have different mechanisms of action, combined with a synergistic effect.
Imidazole can also be combined with amphotericin B, may play a synergistic role in reducing the dosage of amphotericin B, and toxicity. Imidazoles inhibit fungal cell membrane ergosterol, by inhibiting the fungal cells from the inhibition of CYP, and amphotericin B is combined with ergosterol in the fungal cell membrane. Imidazole and polyene combined treatment of fungal infections, in theory, can improve the antibacterial activity. Recent progress fluconazole, fluconazole and amphotericin B combination therapy of candidemia large sample clinical trial.
Has been successfully combined with fluconazole and flucytosine treatment of AIDS patients with cryptococcal meningitis and certain Candida infections. Fungal cell membrane inhibitors (such as imidazole and polyene) and cell wall inhibitors (such as Z and Echinococcus Nick avidin ADM) have a different site of action and mechanism of action, both in combination have synergistic clinical trials needed confirmed.
Over the past 10 years of practice, anti-fungal treatment of two important developments: ① imidazole antifungal treatment and conditions of the fungal disease endemic to succeed; ② liposomal formulations of amphotericin B can increase the dose to improve efficacy and reduce toxicity. More significantly, the use of these drugs to treat AIDS, immune suppression and normal patients, a lot of clinical experience, and thus a new antifungal efficacy and safety of the proposed basis.



[ Back ]
 
Latest Catalog
Main products
Contact Us
Tel: +86-576-88813233
Tel: +86-576-88205808
Fax: +86-576-88229589
Sales Department:
sales@pharm-intermediates.com
crene.pharm@gmail.com
order@pharm-intermediates.com
Msn:
Skype: Call me!
yahoo:
Homepage | About Us | Products | News&Events | Custom Synthesis | Order Infomation | Contact Us
Friendly link: molbase    molbase    Copyright © Taizhou Crene Biotechnology Co.,Ltd.